Reports Q3 revenue $239.46M, consensus $222.68M. “Our exceptional performance this quarter highlights the continued strength of WAKIX and significant market opportunity that remains ahead. I am incredibly proud of our team’s focus and executional excellence, as we delivered very strong results today, which positions Harmony for future growth,” said Jeffrey Dayno, President and CEO of Harmony Biosciences (HRMY). “I continue to have firm conviction in our late-stage pipeline to deliver multiple catalysts over the next several years and, given our strong cash position, we intend to strategically pursue value-enhancing assets to add to our pipeline and build a broader product portfolio of innovative treatments that can help even more patients living with unmet medical needs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Is HRMY a Buy, Before Earnings?
- Harmony Biosciences price target raised to $36 from $35 at Mizuho
- Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- Harmony Biosciences Holdings: Strong Financial Performance and Positive Outlook Drive Buy Rating
- Harmony Biosciences raises FY25 revenue view to $845M-$865M from $820M-$860M